

## **AGC Expands Contract with Novavax for Manufacture of Adjuvant for COVID-19 Vaccine Candidate**

Tokyo, August 18, 2020—AGC a world-leading manufacturer of glass, chemicals and high-tech materials, has announced that AGC Biologics (Headquarters: US), a CDMO<sup>\*1</sup> subsidiary of the company, has expanded its partnership with Novavax, Inc. (Nasdaq: NVAX). AGC Biologics is currently preparing for the manufacture of Matrix-M<sup>TM</sup>, the adjuvant component<sup>\*2</sup> of Novavax' COVID-19 vaccine candidate, NVX-CoV2373 in its Copenhagen facility. AGC Biologics will now expand supply of Matrix-M<sup>TM</sup> adjuvant for the vaccine from its facility in Seattle.

Novavax is a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases. NVX-CoV2373 is a stable, prefusion protein made using Novavax proprietary nanoparticle technology. AGC Biologics is optimizing the process for scaled-up production of Matrix-M<sup>TM</sup> to enable Novavax' ability to deliver significant worldwide supply in 2020 and 2021.

AGC Biologics' global network spans three continents, with cGMP compliant facilities in Japan, the US, and Europe. It provides a wide variety of high value-added services that range from process development to manufacturing of clinical and commercial biopharmaceutical supplies. The AGC Group is committed to helping prevent the spread of COVID-19 and end this pandemic by playing its role in manufacturing COVID-19 vaccines and therapeutics in partnership with pharmaceutical companies.

### Notes:

\*1 CDMO: Contract Development & Manufacturing Organization. A company which is contracted or acts on behalf of another company to handle product manufacturing as well as the development of manufacturing processes.

\*2 Adjuvant component: A substance used in combination to augment or enhance the effect of a vaccine

### REFERENCE

#### ■ About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Matrix-M<sup>TM</sup> is Novavax' proprietary saponin-based adjuvant incorporated in the vaccines developed by the company to enhance the immune response and stimulate high levels of neutralizing antibodies.

Visit the URL below for more details.

URL : [www.novavax.com](http://www.novavax.com).

---

### MEDIA INQUIRIES

Kazumi Tamaki, General Manager, Corporate Communications & Investor Relations Division  
AGC Inc.

(Contact: Yuki Kitano; Tel: +81-3-3218-5603; E-mail: [info-pr@agc.com](mailto:info-pr@agc.com))

\*Handling of personal information is governed by our privacy policy.